Working... Menu

FlexNav EU CE Mark Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03724812
Recruitment Status : Recruiting
First Posted : October 30, 2018
Last Update Posted : April 18, 2019
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
The purpose of this clinical investigation is to characterize the safety of the second-generation FlexNav™ Delivery System for transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in symptomatic severe aortic stenosis patients who are considered of high or extreme risk for surgical aortic valve replacement. Data from the study will be used to support CE Mark of the FlexNav™ Delivery System and Loading System in Europe.

Condition or disease Intervention/treatment Phase
Symptomatic Severe Aortic Stenosis Device: Portico Valve and FlexNav™ Delivery System Not Applicable

Detailed Description:

The FlexNav European Union (EU) study will be conducted as a prospective, multi-center, single-arm investigational study.

Up to 200 high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico™ Transcatheter Aortic Heart Valve implantation via a transfemoral access approach will undergo a Portico valve implant using the second-generation FlexNav Delivery System.

Subject data will be collected at screening, baseline, pre-procedure, peri-procedure, post-procedure, discharge, 30 days, 6 months and one-year from the index procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Devices under investigation in this clinical investigation include the FlexNav™ Delivery System(s) (18 F and 19 F) and FlexNav™ Loading System(s) (Small and Large), which are both approved for investigational use only. Other devices to be used in the clinical investigation include all four (4) market released St. Jude Medical (SJM) Portico™ valve sizes (23mm, 25mm, 27mm and 29mm).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of the Abbott FlexNav™ Delivery System for Portico Transcatheter Aortic Valve Implantation in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis
Actual Study Start Date : February 26, 2019
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Portico valve and FlexNav™ Delivery System
Portico valve implantation with the second-generation FlexNav Delivery system
Device: Portico Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach

Primary Outcome Measures :
  1. Major vascular complications [ Time Frame: At 30 days post index procedure ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Candidates for High Risk classification must meet all the following inclusion criteria:

  1. Subjects must have co‐morbidities such that the local heart team concur the predicted risk of operative mortality is ≥15% or a minimum Society of Thoracic Surgeons (STS) score of 8%.

    a) A candidate who does not meet the STS score criteria of ≥ 8% may be included in the study if at least one surgeon in the local heart team concludes and documents the patient's predicted risk of operative mortality is ≥15%. The surgeon's assessment of operative comorbidities (including frailty indices) not captured by the STS score must be documented in the study case report form as well as in the patient medical record.

  2. Subject is of legal age or older for consent in the host country.
  3. Subject has senile degenerative aortic valve stenosis with echo-derived criteria: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s or doppler velocity index (DVI) <0.25 and an initial aortic valve area (AVA) of ≤1.0 cm2 (indexed Effective Orifice Area (EOA) ≤ 0.6 cm2/m2). (Qualifying AVA baseline measurement must be within 60 days prior to informed consent).
  4. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV.
  5. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
  6. The subject and the treating physician agree that the subject will return for all required post‐procedure follow‐up visits.
  7. Subject's aortic annulus is 19‐27mm diameter as measured by computed tomography (CT) conducted within 12 months prior to informed consent. If a CT i contraindicated and/or not possible to be obtained for certain subjects, a 3D echo and non‐contrast CT of chest and abdomen/pelvis may be accepted.

    All candidates for Extreme Risk classification must meet # 2, 3, 4, 5, 6, 7 of the above criteria, and

  8. After formal consultation with the local heart team (including at least one surgeon) it is agreed that medical factors preclude the subject from undergoing operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Specifically, the probability of death or serious, irreversible morbidity should exceed 50%. The local heart teams' consult notes shall specify the medical or anatomic factors leading to that conclusion and include a printout of the calculation of the STS score to additionally identify the risks in these patients.

Exclusion Criteria:

Candidates will be excluded if any of the following conditions are present:

  1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure.
  2. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified as verified by echocardiography.
  3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+).
  4. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure.
  5. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the LVOT, severe (greater than 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise.
  6. Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count <50,000 cells/mm³).
  7. History of bleeding diathesis or coagulopathy.
  8. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
  9. Untreated clinically significant coronary artery disease requiring revascularization.
  10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.
  11. Need for emergency surgery for any reason.
  12. Hypertrophic cardiomyopathy with or without obstruction (HOCM).
  13. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram.
  14. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  15. Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure.
  16. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be adequately premedicated.
  17. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA).
  18. Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis.
  19. Life expectancy < 12 months from the time of informed consent due to noncardiac co-morbid conditions.
  20. Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5cm or greater; marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding or ulcerated) or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta.
  21. Native aortic annulus size < 19 mm or > 27 mm per the baseline diagnostic imaging.
  22. Aortic root angulation > 70°.
  23. Currently participating in an investigational drug or device study.
  24. Active bacterial endocarditis within 6 months prior to the index procedure.
  25. Bulky calcified aortic valve leaflets in close proximity to coronary ostia.
  26. Non-calcified aortic annulus.
  27. Iliofemoral vessel characteristics that would preclude safe insertion of the FlexNav™ delivery system with or without an arterial introducer sheath such as severe obstructive calcification, or severe tortuosity.
  28. In the judgment of the investigator, a condition that could limit a patient's ability or willingness to participate in the study, comply with study required testing and/or follow- up visits or that could impact scientific integrity of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03724812

Layout table for location contacts
Contact: Paolo Amato +39 335 6140573
Contact: Alicia Kimber, Phd +1 415 917 9696

Layout table for location information
Rigshospitalet Recruiting
Copenhagen, Denmark, 2100
Contact: Lars Soendergaard, MD         
Policlinico San Donato Recruiting
San Donato Milanese, Lombard, Italy, 20097
Contact: Francesco Bedogni, MD         
Kantonsspital St. Gallen Not yet recruiting
St. Gallen, Switzerland, 9007
Contact: Phillip Klaus Haager, MD         
Universitaets Spital Zuerich Recruiting
Zürich, Switzerland, 8091
Contact: Francesco Maisano, MD         
United Kingdom
Royal Victoria Hospital Recruiting
Belfast, United Kingdom, BT12 6BA
Contact: Ganesh Manoharan, MD         
Sponsors and Collaborators
Abbott Medical Devices

Layout table for additonal information
Responsible Party: Abbott Medical Devices Identifier: NCT03724812     History of Changes
Other Study ID Numbers: ABT-CIP-10260
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Abbott Medical Devices:
Aortic Stenosis
FlexNav™ Delivery System
Portico Delivery System
Transcatheter Aortic Valve Replacement
Heart Valve Disease
High surgical risk

Additional relevant MeSH terms:
Layout table for MeSH terms
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction